Characterisation of a novel group B oncolytic adenovirus, ColoAd1

Characterisation of a novel group B oncolytic adenovirus, ColoAd1

Näytä muut versiot (1)

<p>Developing high potent oncolytic virus with multimodal antitumour capabilities is crucial for realizing the full potential of oncolytic virotherapy in cancer treatment. ColoAd1 is a novel replicating chimeric group B adenovirus recently bioselected from a large library of recombinant virus...

Bibliografiset tiedot
Päätekijä:	Di, Y
Muut tekijät:	Seymour, L
Aineistotyyppi:	Opinnäyte
Kieli:	English
Julkaistu:	2011
Aiheet:	Oncology

Samankaltaisia teoksia

Characterisation of a novel group B oncolytic adenovirus, ColoAd1
Tekijä: Di, Y, et al.
Julkaistu: (2011)

Arming ColoAd1 with tumor necrosis factor alpha and lymphotoxin alpha
Tekijä: Koelen, J
Julkaistu: (2015)

Investigating the oncolytic properties of a group B adenovirus on cancer cells and its effects on the local immune response
Tekijä: Calderon, H
Julkaistu: (2017)

Exploring the relationship between cancer metabolism and oncolytic adenoviruses
Tekijä: Dyer, A
Julkaistu: (2021)

Bioprocessing of oncolytic group B adenovirus for scalable production
Tekijä: Cooper, L
Julkaistu: (2014)

Exploring the effects of nutrient deprivation and waste accumulation on T cells and oncolytic adenoviruses; in order to create immune activators for tumour therapy
Tekijä: Frost, SC
Julkaistu: (2020)

Oncolytic Replication of E1b-Deleted Adenoviruses
Tekijä: Pei-Hsin Cheng, et al.
Julkaistu: (2015-11-01)

Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus
Tekijä: Illingworth, S, et al.
Julkaistu: (2017)

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Tekijä: Sam Illingworth, et al.
Julkaistu: (2017-06-01)

Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35
Tekijä: Ryosuke Ono, et al.
Julkaistu: (2021-03-01)

A Renaissance for Oncolytic Adenoviruses?
Tekijä: Paola Blanchette, et al.
Julkaistu: (2023-01-01)

Oncolytic Adenoviruses in Cancer Treatment
Tekijä: Ramon Alemany
Julkaistu: (2014-02-01)

Oncolytic Adenoviruses in Gastrointestinal Cancers
Tekijä: Raquel T. Yokoda, et al.
Julkaistu: (2018-03-01)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
Tekijä: Virginia Laspidea, et al.
Julkaistu: (2022-04-01)

Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus
Tekijä: Warren Floyd, et al.
Julkaistu: (2023-07-01)

Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer
Tekijä: Xiao-yu Chen, et al.
Julkaistu: (2024-11-01)

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
Tekijä: Samuel T. Pellom, et al.
Julkaistu: (2021-04-01)

Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development
Tekijä: Tiffany Y. Ho, et al.
Julkaistu: (2021-09-01)

Investigation of strategies to enhance the delivery of oncolytic vaccinia virus
Tekijä: Hill, C
Julkaistu: (2020)

Adenovirus as a Vector and Oncolytic Virus
Tekijä: Wataru Matsunaga, et al.
Julkaistu: (2023-06-01)

Oncolytic adenovirus for treatment of malignant ascites
Tekijä: Akseli Hemminki, et al.
Julkaistu: (2022-09-01)

Increasing the Efficacy of Oncolytic Adenovirus Vectors
Tekijä: William S. M. Wold, et al.
Julkaistu: (2010-08-01)

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
Tekijä: Sharmila Nair, et al.
Julkaistu: (2021-01-01)

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
Tekijä: Hanni Uusi-Kerttula, et al.
Julkaistu: (2015-11-01)

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
Tekijä: Dyer, A, et al.
Julkaistu: (2016)

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Tekijä: Lei, J, et al.
Julkaistu: (2018)

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells
Tekijä: Janet Lei, et al.
Julkaistu: (2018-06-01)

Pharmacoproteomic characterisation of human colon and rectal cancer
Tekijä: Frejno, M
Julkaistu: (2016)

Oncolytic adenoviruses and immunopeptidomics: a convenient marriage
Tekijä: Marc Garcia‐Moure, et al.
Julkaistu: (2024-04-01)

HSF1 overexpression enhances oncolytic effect of replicative adenovirus
Tekijä: Deng Youwen, et al.
Julkaistu: (2010-05-01)

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators
Tekijä: Arthur Dyer, et al.
Julkaistu: (2017-03-01)

Species D Adenoviruses as Oncolytic Viral Vectors
Tekijä: Brianna L. Bullard, et al.
Julkaistu: (2020-12-01)

The gamble between oncolytic virus therapy and IFN
Tekijä: Qingbo Li, et al.
Julkaistu: (2022-08-01)

Characterisation of Topoisomerase 1-cleavage complex repair
Tekijä: Lascaux, P
Julkaistu: (2024)

Novel Chitosan-Coated Liposomes Coloaded with Exemestane and Genistein for an Effective Breast Cancer Therapy
Tekijä: Shwetakshi Sharma, et al.
Julkaistu: (2024-02-01)

Improving intraperitoneal adenovirus virotherapy for ovarian cancer
Tekijä: Thoma, CMM
Julkaistu: (2011)

Identification and characterisation of determinants of genome stability in response to a double-strand break
Tekijä: Kasparek, TR
Julkaistu: (2013)

Relevance of specific oncolytic adenovirus in regulating PD-L1 expression in prostate cancer
Tekijä: Di Zhang, et al.
Julkaistu: (2023-05-01)

In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells
Tekijä: Victor A. Naumenko, et al.
Julkaistu: (2022-07-01)

Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy
Tekijä: Daoyuan Xie, et al.
Julkaistu: (2023-11-01)